BSE Live
Mar 19, 16:01Prev. Close
1268.20
Open Price
1258.15
Bid Price (Qty.)
1241.90 (10)
Offer Price (Qty.)
1248.40 (101)
NSE Live
Mar 19, 15:59Prev. Close
1268.50
Open Price
1253.90
Bid Price (Qty.)
1239.20 (356)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Cipla (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,324.99 | 901.31 | 838.36 | 807.98 | 709.84 | |
| Net CashFlow From Operating Activities | 1,041.68 | 373.27 | 380.20 | 334.42 | 277.16 | |
| Net Cash Used In Investing Activities | -562.23 | -578.47 | -687.25 | -485.97 | -389.23 | |
| Net Cash Used From Financing Activities | -471.61 | 178.92 | 254.84 | 238.56 | 145.35 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 7.84 | -26.28 | -52.21 | 87.01 | 33.28 | |
| Cash And Cash Equivalents Begin of Year | 53.00 | 79.28 | 131.49 | 44.48 | 11.20 | |
| Cash And Cash Equivalents End Of Year | 60.84 | 53.00 | 79.28 | 131.49 | 44.48 |
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
23.02.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth